Status:
COMPLETED
Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Gouty Arthritis
Eligibility:
All Genders
Brief Summary
This was a non-interventional, retrospective, cross-sectional, descriptive study, conducted on the National Health Data System (Système National des Données de Santé, SNDS). The study did not modify ...
Eligibility Criteria
Inclusion
- Received at least one reimbursement of Ilaris® from 08 April 2018 to 07 April 2020.
- Benefited from at least one of the following healthcare consumptions during 3 years prior to index date:
- o At least one hospitalization with a main diagnosis or a related diagnosis in a Medical Unit Summary or a significant associated diagnosis in a Standardized Discharge Summary corresponding to the International Classification of Diseases, 10th Revision (ICD-10) code:
- M10.0 "Idiopathic gout"
- M10.1 "Saturnine gout"
- M10.2 "Medicated gout"
- M10.3 "Gout due to impaired renal function"
- M10.4 "Other secondary gout"
- M10.9 "Gout, unspecified"
- And/or an active long-term disease (Affection Longue Durée, ALD) with an ICD-10 code: "M10 Gout"
- And/or at least one dispensation of colchicine and urate-lowering therapy (allopurinol and/or febuxostat and/or benzbromarone and/or probenecid) at any time.
Exclusion
- None
Key Trial Info
Start Date :
June 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 29 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05964946
Start Date
June 24 2020
End Date
July 29 2022
Last Update
July 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Paris, France, 92506